companies / peptinov-fr
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-07 json
| total_raised | 2,700,0002.7M | ○ |
|---|---|---|
| founded | null | |
| hq | France | |
| industry | unknown | |
| stage | null |
Peptinov develops peptide-based active immunotherapies that train patients to produce antibodies against their own pathogenic targets. It serves patients with chronic inflammatory diseases and the pharma partners that license its platform assets. The peptide-based active vaccination approach is positioned as a cheaper, longer-acting alternative to monoclonal antibody therapy.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2023-07-01 | grant | 2,700,0002.7M | null | ○ |
Vue.js 2.6.14, vue 2.6.14
| fact | status | src |
|---|---|---|
| Grant, $2.7M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |